Matthew Riley - Lucid Diagnostics Director Relations
| LUCD Stock | USD 1.34 0.05 3.88% |
Director
Matthew Riley is Director Relations of Lucid Diagnostics
| Address | 360 Madison Avenue, New York, NY, United States, 10017 |
| Phone | 917 813 1828 |
| Web | https://www.luciddx.com |
Lucid Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.7917) % which means that it has lost $0.7917 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.3124) %, meaning that it created substantial loss on money invested by shareholders. Lucid Diagnostics' management efficiency ratios could be used to measure how well Lucid Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 19, 2026, Return On Tangible Assets is expected to decline to -1.44. The current year's Return On Capital Employed is expected to grow to -5.48. The current year's Net Tangible Assets is expected to grow to about 23.7 M, whereas Total Assets are forecasted to decline to about 24 M.Similar Executives
| Found 3 records | DIRECTOR Age | ||
| Yuwen Zhang | Sharps Technology | 34 | |
| Erik Sims | Opus Genetics | N/A | |
| Mike Ciaffi | Scilex Holding | N/A | |
Management Performance
| Return On Equity | -3.31 | ||||
| Return On Asset | -0.79 |
Lucid Diagnostics Leadership Team
Elected by the shareholders, the Lucid Diagnostics' board of directors comprises two types of representatives: Lucid Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lucid. The board's role is to monitor Lucid Diagnostics' management team and ensure that shareholders' interests are well served. Lucid Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lucid Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lishan MD, Chairman CEO | ||
| Joseph MD, Strategic Cofounder | ||
| Deepika Lakhani, Chief Officer | ||
| Michael Gordon, General Secretary | ||
| Michael Parks, Vice Relations | ||
| Adrian Miller, VP Relations | ||
| Amitabh MD, Strategic Cofounder | ||
| Matthew Riley, Director Relations | ||
| Shaun MBA, President COO | ||
| Brian MD, Chief Officer | ||
| Victoria MD, Chief Officer | ||
| Helen Moinova, CoFounder Advisor | ||
| Richard Yazbeck, Chief Officer | ||
| Dennis CPA, Chief Officer |
Lucid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lucid Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.31 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (9.71) % | ||||
| Current Valuation | 201.71 M | ||||
| Shares Outstanding | 131.1 M | ||||
| Shares Owned By Insiders | 35.35 % | ||||
| Shares Owned By Institutions | 25.56 % | ||||
| Number Of Shares Shorted | 7.01 M | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 38.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value - what Lucid Diagnostics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.